MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344
MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum
MEI Update from Study Evaluating Voruciclib with Venetoclax in Patients with AML
MEI Pharma Reports Second Quarter Fiscal Year 2024 Results
MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344
MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023
MEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational Highlights
MEI Pharma to Present at the Stifel 2023 Healthcare Conference
MEI Pharma Declares Special Cash Dividend of $1.75 Per Share of Common Stock